The goal of the present clinical descriptive study is to characterize and quantify the potential hormonal chronobiological differences between individuals with type 2 diabetes (T2D) and healthy age and weight-matched controls as either circadian aligned or misaligned. The investigators hypothesize that individuals with T2D have a misaligned and different circadian rhythmicity of circadian biomarkers (melatonin and cortisol) than controls, and that this difference in turn is related to 24h hormonal fluctuations, behaviour, and metabolic-, cardiac-, and cognitive parameters. Participants will be asked to: * fill-out a diary on eating and sleeping habits for 30 days * wear an actigraphy and continuous glucose monitor for 10-14 days * stay overnight at the research facility, including continuous blood sampling and polysomnography
T2D is associated with cognitive dysfunction and an increased risk of developing dementia. This negative effect on cognition is worsened by T2D duration, yet the mechanisms are unknown. Sleep disturbances increase peripheral insulin resistance, and is associated with the development of T2D, temporarily worsened cognitive function, and the development of cognitive impairment. In turn, T2D is associated with circadian misalignment (a condition where the internal physiological clock is unaligned with the external behavior). A major external signal (also known as zeitgeber) for synchronizing the internal and external clock is sleep in accordance with the day-night cycle. Determining the circadian rhythm of an individual and whether it is aligned or misaligned is complex and can't be done by one measurement. However, melatonin and cortisol are often used as "circadian biomarkers" due to significant and well-defined circadian rhythm profiles. Another measure of the circadian phase is the timing of melatonin production under dim light conditions (dim light melatonin onset) which is an individual phase marker depending on the persons habitual time of sleep. Most studies focusing on circadian alignment in an everyday setting have used questionnaires, and to our knowledge, no studies have described 24-h circadian oscillations between individuals with T2D and healthy age and weight matched controls. Mapping these potential differences could help explain the pathophysiological mechanisms behind T2D and circadian misalignment. The Cir-D-Brain study is a clinical descriptive study. The study comprises of an information visit, a screening visit, a midway visit (2 weeks after screening), a 24-h in-hospital day (a day between the midway visit and the final visit), and a final visit (2 weeks after the midway visit). Participants will keep a diary on eating and sleeping habits for all 30 days. At the midway visit, participants will be equipped with an actigraphy and a continuous glucose monitor. At the 24-h in-hospital day, participants will have their blood sampled every third hour for 24 hours to measure their circadian rhythm, every hour from 6 pm till 12 am to map dim light melatonin onset, and at wake-up to map cortisol awakening response. At the 24-h in-hospital day, participants will furthermore have their sleep stages measured by polysomnography. The study will include 30 participants with T2D and 30 age and BMI matched controls. The specific objectives are: 1. To characterize and quantify the hormonal chronobiological differences between individuals with T2D and healthy matched controls measured by circadian biomarkers. 2. To relate the findings to 24-h hormonal fluctuations, different patterns in metabolism, behavioural circadian rhythms differences (sleep-wake and eating habits), sleep stages, glycaemic variability, inflammation, heart rate variability, and cognition.
Study Type
OBSERVATIONAL
Enrollment
60
Steno Diabetes Center Copenhagen
Herlev, Denmark
RECRUITINGMelatonin oscillations (amplitude, peak, mesor, phase, period length (TAU))
Blood samples
Time frame: 24-hour in-hospital day, blood samples taken every third hour for 24 hours (9 timepoints in total)
Cortisol oscillations (amplitude, peak, mesor, phase, period length (TAU))
Blood samples
Time frame: 24-hour in-hospital day, blood samples taken every third hour for 24 hours (9 timepoints in total)
Dim light melatonin onset
Blood samples (pg/ml)
Time frame: 24-hour in-hospital day, blood samples taken every hour from 18:00 until 00:00 (7 timepoints in total)
Phase angle (time between dim light melatonin onset and sleep)
Blood samples
Time frame: 24-hour in-hospital day, blood samples taken every hour from 18:00 until 00:00 (7 timepoints in total)
Cortisol awakening response
Blood samples (pg/ml)
Time frame: 24-hour in-hospital day, blood samples taken at wake up, and 15-, 30-, and 60-minutes post-wake up
Diary on sleeping habits
Expanded Consensus Sleep Diary (time in bed, time to fall asleep, number of awakenings and durations, time of final awakening, time to get out of bed, total sleep time, sleep quality, daytime sleepiness, number of naps and duration, number and last time of alcohol consumption, number and last time of coffein consumption, use of sleep medicine)
Time frame: 30 days
Diary on eating window
The eating window (initiation of first consumption and termination of last consumption of food)
Time frame: 30 days
Glycaemic variability
Continuous glucose monitor (amplitude (mmol/L), frequency, and duration of the fluctuation, mean glucose (mmol/L), time in range, time in hyperglycemic and hypoglycemic range, area under the curve)
Time frame: 10-14 days
Sleep and waking states
Actrigraph worn on the wrist of the non-dominant hand (acceleration at different times)
Time frame: 10-14 days
Heart rate variability (fluctuations in time intervals between adjacent heart beats)
Measured continuously by the polysomnograph (ms)
Time frame: 24-hour in-hospital day
Sleep architecture
Polysomnography (minutes and percentages). Sleep stages (N1, N2, N3, rapid eye movement (REM)), total time asleep, sleep latency, REM sleep latency, arousals, awakenings, total sleep efficiency.
Time frame: 24-hour in-hospital day
Cognition (verbal memory)
Rey Auditory Verbal Learning Test (RAVLT)
Time frame: 24-hour in-hospital day
Cognition (psychomotor speed and executive function)
Trail Making Test (TMT) part A and B ), Symbol Digit Modalities Test (SDMT)
Time frame: 24-hour in-hospital day
Cognition (executive function)
WAIS-III Letter-Number Sequencing test, Verbal fluency test (letters S and D)
Time frame: 24-hour in-hospital day
Cognition (sustained attention)
Rapid Visual Processing (RVP) test from the Cambridge Neuropsychological Test Automated Battery (CANTAB)
Time frame: 24-hour in-hospital day
Cognition (verbal IQ)
Danish Adult Reading Test (DART) (equivalent to the National Adult Reading Test; NART)
Time frame: 24-hour in-hospital day
Insulin oscillations (amplitude, peak, mesor, phase, period length (TAU))
Blood samples.
Time frame: 24-hour in-hospital day, blood samples taken every third hour for 24 hours (9 timepoints in total)
C-peptide oscillations (amplitude, peak, mesor, phase, period length (TAU))
Blood samples.
Time frame: 24-hour in-hospital day, blood samples taken every third hour for 24 hours (9 timepoints in total)
TSH oscillations (amplitude, peak, mesor, phase, period length (TAU))
Blood samples.
Time frame: 24-hour in-hospital day, blood samples taken every third hour for 24 hours (9 timepoints in total)
Glucose oscillations (amplitude, peak, mesor, phase, period length (TAU))
Blood samples.
Time frame: 24-hour in-hospital day, blood samples taken every third hour for 24 hours (9 timepoints in total)
Glucagon oscillations (amplitude, peak, mesor, phase, period length (TAU))
Blood samples.
Time frame: 24-hour in-hospital day, blood samples taken every third hour for 24 hours (9 timepoints in total)
Glucagon-like peptide-1 (GLP-1) oscillations (amplitude, peak, mesor, phase, period length (TAU))
Blood samples.
Time frame: 24-hour in-hospital day, blood samples taken every third hour for 24 hours (9 timepoints in total)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.